Latest Conference Articles

SK pharmteco boosts US peptide synthesis and purification capabilities, advancing reliable large-scale manufacturing for biopharma innovation.

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.

Spotlighting global biopharma innovation, the event will unite leaders to discuss digitalization, sustainable manufacturing, and future-ready development.

As the conference approaches, scientists are reviewing new technologies that enhance manufacturing process control, product integrity, and regulatory compliance through automation and sustainable materials.

The company will also highlight its sustainability strategies and quality solutions at the event.

The IPEC-Americas event focuses exclusively on excipients and brings buyers and suppliers together.

The new label for prefilled syringes, in conjunction with innovations from SCHOTT Pharma, enables integrated tamper-evidence and digital tracking across the supply chain.

At the Cell and Gene Meeting on the Mesa, a panel discussion was held on advanced therapy production and how it demands modular platforms, automation, and data governance to drastically improve patient access and affordability.

Vienna to host BIO-Europe 2025, connecting top biopharma companies for collaborations and pipeline development.

Finalists for CPHI Frankfurt Pharma Awards 2025 showcase innovation in drug development, advanced manufacturing, and future industry leaders.

The company, under parent ICE Pharma, will celebrate its past achievements, present its expertise and plans for the future, and unveil a “100 Years” logo.

The company has expanded its CDMO offerings in recent years, adding to decades of experiences in solutions such as moisture management.

The 2024 edition of the annual conference, held in Milan, attracted more than 59,000 professionals from across the bio/pharmaceutical landscape.

Merck’s Sanat Chattopadhyay called for stronger leadership, data-driven oversight, and shared accountability to raise pharmaceutical quality standards.

Susan J. Schniepp, Distinguished Fellow, Regulatory Compliance Associates, joins PDA CEO Glenn Wright and Melissa Seymour, Executive Vice President, Global Quality, Eli Lilly and Company, to talk about the regulatory and quality topics discussed at the 2025 PDA Regulatory Conference.

AI can offer a strategic blueprint for GxP compliance, risk mitigation, and human-led operational excellence.

FDA experts at PDA 2025 urges pharma to adopt holistic quality systems, strengthening 483 responses & post-warning letter remediation for compliance excellence.

Charles Gibbons of Lachman Consultants and Michael Grischeau of AbbVie stressed AI governance, data integrity, and human oversight as essential to applying digital tools across labs and supply chains.

Bothe data integrity and quality of data are critical for drug discovery, manufacturing efficiency, regulatory compliance, and patient safety.

Glenn Wright previews the 34th PDA Regulatory Conference, spotlighting AI, quality culture, FDA trends, and collaboration shaping industry progress.

The trade show is expected to draw 35,000 attendees to a show floor netting more than 1 million square feet.

In contrast to earlier conferences in 2025, experts interviewed as part of the BIO conference in Boston did not come to a consensus about lasting impacts of recent changes in US government policy.

The department’s newly announced partnerships were part of a weeklong visit that included discussions held at BIO 2025.

PharmTech Group spoke with Andy Burns, vice-president of MDI Business Development at Kindeva, ahead of BIO 2025 to find out what’s new in pulmonary drug delivery.

In discussions at INTERPHEX 2025, company representatives seized upon several common themes, most notably safety, sustainability, and the increasing utility of automation.

Christy Eatmon of Thermo Fisher Scientific reviewed her company’s experience at CPHI Americas 2025 and discussed recent industry trends that are driving strategic partnerships.

The concerns of industry experts expressed at INTERPHEX in April 2025 are still pertinent in an uncertain global political climate.

BioPharm International® spoke with Lun Xin, associate director at WuXi Biologics, about high-concentration biologics and some of the biggest challenges associated with their formulation.